Recommendation Framework for CADTH Common Drug Review (CDR) and pan-Canadian Oncology Drug Review (pCODR) Programs
In collaboration with the participating jurisdictions and with input from stakeholders, CADTH has established a single recommendation framework to support the drug expert committees (the CADTH Canadian Drug Expert Committee [CDEC] and the CADTH pCODR Expert Review Committee [pERC]) in making recommendations to the participating jurisdictions to guide their reimbursement decisions.
To learn more about the new recommendation framework for the CADTH Drug Review programs, please consult the following documents:
Of note, CADTH has revised the recommendation options, effective for all submissions and resubmissions targeting the April 2016 CDEC meeting. Previous recommendation options for a drug under review were the following: list, list with clinical criteria and/or conditions, do not list at the submitted price, or do not list and provide reasons for the recommendation. The revised recommendation options for a drug under review are as follows: reimburse, reimburse with clinical criteria and/or conditions or do not reimburse and provide reasons for the recommendation.
Minimum Period of 120 Calendar Days for Advance Notification of Anticipated Submissions and Resubmissions
CADTH will be implementing changes to the CDR and pCODR procedures that will require all manufacturers/submitters to provide a minimum of 120 calendar days advance notification for anticipated submissions and resubmissions. This requirement will apply to all CADTH Pre-Submission Information Requirements Forms received on May 1, 2016 and onwards, and would pertain to all submissions and resubmissions filed on or after September 1, 2016.
For more detail about this new requirement, please click on the following link.